FY2025 Earnings Estimate for LRMR Issued By HC Wainwright

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at HC Wainwright reduced their FY2025 earnings per share estimates for Larimar Therapeutics in a research note issued on Monday, December 16th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($1.77) per share for the year, down from their prior forecast of ($1.57). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Larimar Therapeutics' FY2026 earnings at ($1.99) EPS.

Several other equities analysts have also recently weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday, November 19th. Wedbush assumed coverage on Larimar Therapeutics in a report on Thursday, October 3rd. They set an "outperform" rating and a $22.00 price target on the stock. Baird R W raised Larimar Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 4th. Robert W. Baird began coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an "outperform" rating and a $16.00 price objective for the company. Finally, Oppenheimer initiated coverage on Larimar Therapeutics in a report on Wednesday, October 16th. They issued an "outperform" rating and a $26.00 target price on the stock. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Larimar Therapeutics currently has a consensus rating of "Buy" and an average price target of $20.43.

Larimar Therapeutics Stock Down 4.3 %

Shares of LRMR stock traded down $0.18 during trading hours on Thursday, reaching $3.98. 1,552,424 shares of the stock traded hands, compared to its average volume of 626,714. The firm has a market capitalization of $253.95 million, a PE ratio of -3.46 and a beta of 0.86. Larimar Therapeutics has a 1-year low of $3.01 and a 1-year high of $13.68. The business has a fifty day moving average price of $6.97 and a 200 day moving average price of $7.65.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.13. During the same period last year, the company posted ($0.21) EPS.

Hedge Funds Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. Janus Henderson Group PLC raised its stake in shares of Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company's stock valued at $36,379,000 after acquiring an additional 1,189,467 shares during the last quarter. Driehaus Capital Management LLC raised its position in Larimar Therapeutics by 20.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,314,106 shares of the company's stock valued at $9,527,000 after purchasing an additional 225,879 shares during the last quarter. Millennium Management LLC boosted its stake in Larimar Therapeutics by 30.2% in the second quarter. Millennium Management LLC now owns 1,018,135 shares of the company's stock worth $7,381,000 after purchasing an additional 235,865 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Larimar Therapeutics by 37.7% during the second quarter. Point72 Asset Management L.P. now owns 603,581 shares of the company's stock worth $4,376,000 after purchasing an additional 165,181 shares during the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of Larimar Therapeutics by 32.6% in the third quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company's stock valued at $2,715,000 after buying an additional 102,009 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.